TITLE

SWOT Analysis

PUB. DATE

June 2003

SOURCE

Celera Genomics SWOT Analysis;June 2003, p5

SOURCE TYPE

SWOT Analysis

DOC. TYPE

Company Report

ABSTRACT

Provides a business analysis of Celera Genomics Group, a biopharmaceutical company that has mapped out the human genome and is part of the Applera Corp. and generates and commercializes genomic information to accelerate the understanding of biological processes, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths, including benefits derived from its robust alliance networking with leading pharma players and expertise in genomics based technology; Weaknesses, including continuous dependence on collaborative income and financial support from its parent firm Applera Corp. and poor financial performance for the fiscal year ended June 2003; Opportunities for improvement, including expansion of its preclinical pipeline with in-house discovered genomics-based drugs and acquisition of small and innovative biotech players to expand its pipeline; Threats to the company, including clinical pipeline failures in the inflammation and oncology programs and inability to fully capitalize its genomics expertise.

ACCESSION #

13411925

Tags: BUSINESS enterprises -- Finance;  BUSINESS cycles;  INDUSTRIAL location;  FINANCIAL performance;  CORPORATE profits;  CORPORATIONS -- Growth;  CELERA Genomics Group (Company);  PHARMACEUTICAL industry;  HEALTH care industry;  CORPORATIONS;  STRATEGIC alliances (Business);  GENOMICS

 

Related Articles

• Key Facts.  // Celera Genomics SWOT Analysis;June 2003, p4 

  Presents key facts about Celera Genomics Group, a biopharmaceutical company that has mapped out the human genome and is part of the Applera Corp. and generates and commercializes genomic information to accelerate the understanding of biological processes. Address and contact information;...

• Celera Genomics SWOT Analysis.  // Celera Genomics SWOT Analysis;June 2003, p1 

  Presents an overview of Celera Genomics Group, a biopharmaceutical company that has mapped out the human genome and is part of the Applera Corp. and generates and commercializes genomic information to accelerate the understanding of biological processes. Company overview, including revenues...

• Company Overview.  // Celera Genomics SWOT Analysis;June 2003, p4 

  Presents an overview of Celera Genomics Group, a biopharmaceutical company that has mapped out the human genome and is part of the Applera Corp. and generates and commercializes genomic information to accelerate the understanding of biological processes. Revenues generated in fiscal year ended...

• SWOT Analysis.  // Isis Pharmaceuticals, Inc. SWOT Analysis;November 2004, p5 

  Provides a business analysis of Isis Pharmaceuticals Inc., a pharmaceutical company primarily engaged in the development and commercialization of human therapeutic drugs, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths, including...

• Isis Pharmaceuticals, Inc. SWOT Analysis.  // Isis Pharmaceuticals, Inc. SWOT Analysis;November 2004, p1 

  Presents an overview of Isis Pharmaceuticals Inc., a pharmaceutical company primarily engaged in the development and commercialization of human therapeutic drugs. Company overview, including revenues generated in the fiscal year ended December 2003 and location of the company's headquarters; Key...

• SWOT Analysis.  // Barrier Therapeutics, Inc. SWOT Analysis;Oct2007, p5 

  No abstract available.

• SWOT Analysis.  // Purdue Pharma SWOT Analysis;May2007, p5 

  A business analysis of Purdue Pharma LP, a pharmaceutical company conducting pioneering research on persistent pain, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include strong market position. Weaknesses include negative...

• Company Overview.  // King Pharmaceuticals SWOT Analysis;Feb2007, p4 

  An overview of King Pharmaceuticals Inc., a vertically integrated pharmaceutical company that develops, manufactures, markets and sells prescription pharmaceutical products, is presented. Data is included on revenues generated in fiscal year 2005, as well as principal business offered, including...

• SWOT Analysis.  // GlaxoSmithKline, PLC SWOT Analysis;March 2004, p5 

  Provides a business analysis of GlaxosmithKline PLC that discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related consumer products, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company....

Read the Article